

SHANGYA Technology Co., Ltd

(Original SINGBAO International Co., Ltd)

INVESTOR CONFERENCE DECEMBER 25, 2023

DISCLAIMER

- The figures of briefing consolidated financial statements are compiled in accordance with the guidelines of the International Financial Reporting Standards (IFRSs) approved by the securities issuer's financial statements and prepared in accordance with the International accounting standards, interpretation and interpretation bulletins, and the verification by certified accountants.
 - The Company has not issued any financial forecast. The financial statements, the business descriptions and the Company 's future business prospects in this Briefing may differ from those of actual operations in the future. Such differences may include changes in market demand, price fluctuations, International economic conditions and fluctuations of exchange rate, and other risks that the Company cannot grasp.
- The information gathered in this Briefing is from various sources within and outside the Company. If there is any change in the future, please refer to the information announced by the Public Information Observatory (https://mops.twse.com.tw).


CONTENTS

- Part 2 State of Operation
- Part 3 Financial Status for the Past 3 Years


Company Profile

- Stock Code : 6130
- Name of Company : SHANGYA Technology Co., Ltd
- Person in Charge : Chairman and CEO , Huang Kun-Jian
- Registered Capital : NTD 443,000,000
- Main Business Line : Pharmaceutical , Solar Energy and IC Design

Investment Framework



Product Portfolio Revenue



Financial Structure for the Past 3 Years - Debt Ratio

100.00% -			
90.00%			
80.00% -			
70.00%			
60.00% -			
50.00% -			
40.00% -			
30.00% -			
20.00% -			17.91%
10.00% -		14.16%	
0.00% -	2020	2021	2022


Debt Repayment Capacity for the Past 3 Years - Current Ratio

700.00%			
600.00%			659.77%
500.00%			_
400.00%			_
300.00%			_
200.00%			_
100.00%		139.10%	
0.00%			
	2020	2021	2022


Debt Repayment Capacity for the Past 3 Years - Quick Ratio

700.00%				
600.00%			629.84%	
500.00%				
400.00%			_	
300.00%			_	
200.00%			_	
100.00%		110.82%	_	
0.00%	<u>24.53%</u> 2020	2021	2022	

Net Operating Revenue for the Past 3 Years



EPS for the Past 3 Years



Income Statement for the Recent Years

Item	2023. 1-9	2022. 1-9	Growth Rate %
Net Sales	177, 781	66, 490	167.38
Gross Profit	65, 884	31, 353	110.14
Operating Expenses	65,759	49, 517	32.80
Operating Income(Loss)	125	(18, 164)	100.69
Non-Operating Income and Expenses	50, 242	(5, 302)	1047.60
Pre-Tax Income	50, 367	(23, 466)	314.64
Net Income	46, 828	(22,990)	303.69
EPS (dollar)	0.68	(0.55)	223.64

Future Prospects

• A. Generic Drug : Strengthen the layout of specialty medication and develop advantageous generic drugs through the information from Drug Supply Information Platform of FDA. Pursue domestic representation for high-end generic drugs and expand partnerships within the medical community; furthermore, expand market share and influence in the medical retail sector; establish a performanceoriented organizational management approach; strengthen the layout of marketing channels; groom excellent agents and distributors. Finally, enhance the competitiveness and establish the foundation for sustainable development and long-term profitability.

◆ B. Solar Energy : Continuously develop suitable locations for solar power generation, and focus on the development of green energy industry. Actively invest in the solar energy sector and related green energy, and aligning with national energy policies and strategies. In addition, we strive to contribute to environmental conservation, dedicating our efforts to the future of the planet.

Future Prospects

◆ C. Power IC : Through proactive talent development programs and recruitment, we are committed to providing innovative technologies and higher-quality products in the design of power IC and related integrated services for automotive, small appliances, and low earth orbit satellite applications. We aims to exceed customer expectations by delivering both existing and newly developed products, thereby solidify and strengthen our market share. In addition, increasing the versatility and quality of our products, ultimately enhancing operational efficiency.

• D. Future Operation and Development: Committed to diversification and integrate limited corporate resources, our company provide improved operational environments and more effective risk management. By continuously innovating with advanced technologies and improved method, we assess prospective investment projects to establish the foundation for our company's diversified development and sustainable operations.

THANK YOU FOR LISTENING